You are here
October 30, 2013
Early stem cell transplants evaluated for non-Hodgkin's lymphoma patients at high risk of early relapse
Remissions last longer, but survival not affected
MAYWOOD, Ill. – Performing early stem cell transplants in patients with aggressive non-Hodgkin’s lymphoma does not improve overall survival in high-risk patients, according to a study published in the New England Journal of Medicine.
But early transplantation does appear to be beneficial among a small group of patients who are at the very highest risk, the study found.
Lead author is Patrick Stiff, MD, director of Loyola University Medical Center’s Cardinal Bernardin Cancer Center. The study was developed by the SWOG cancer research cooperative group and funded by the National Cancer Institute. Stiff is chair of the SWOG Bone Marrow and Stem Cell Transplantation Committee.
The traditional first-line therapy for aggressive non-Hodgkin’s lymphoma is a combination of four chemotherapy drugs, as Dr. Stiff explains in this video. In recent years, physicians have added a fifth drug, the monoclonal antibody rituximab. This five-drug regimen is known as R-CHOP. The treatment typically puts patients into remission. But many patients relapse and go on to get an autologous stem cell transplant after second-line chemotherapy.
The study was designed to determine whether doing an early stem cell transplant - without first waiting to see whether a patient relapses - would increase survival.
The clinical trial included 40 sites in the United States and Canada. In addition to SWOG, the study included the Eastern Cooperative Oncology Group, Cancer and Leukemia Group B and Canadian NCIC Clinical Trials Group.
The study included 397 patients who were in defined groups of high risk or intermediate high risk of relapsing. After initial chemotherapy, those who responded were randomly assigned to receive an autologous stem cell transplant (125 patients) or to a control group of 128 patients who received three additional cycles of the R-CHOP regimen. Enrollment began in 1999 and ended in 2007. (Some of the patients in the beginning of the study did not receive rituximab.)
After two years, 69 percent of the transplantation patients had no disease progression, compared with 55 percent of the control group - a statistically significant difference. However, the difference in two-year survival rates (74 percent in the transplantation group and 71 percent in the control group) was not statistically significant. This is probably because patients in the control group who relapsed were later offered stem cell transplants, Stiff and colleagues wrote.
But while stem cell transplants did not improve overall survival among the entire group of high risk and high intermediate risk patients, the subset of high risk patients did appear to receive both a remission and survival benefit. A retrospective analysis of the data showed that among these high risk patients, the two-year survival rate was 82 percent in the transplantation group and 64 percent in the control group.
“Early transplantation and late transplantation achieve roughly equivalent overall survival in the combined risk groups,” researchers concluded, yet “early transplantation appears to be beneficial for the small group of patients presenting with high risk disease."
Stiff said this finding “hopefully will trigger discussions between such patients and their physicians as to the feasibility of doing early transplants."
An autologous stem cell transplant enables a patient to tolerate very high doses of chemotherapy and/or radiation. In addition to killing cancer cells, this high dose treatment also destroys the patient’s immune system cells. So prior to treatment, stem cells are removed from the patient’s blood or bone marrow. After the chemotherapy and/or radiation, these stem cells are infused back into the patient. The stem cells develop into new immune cells, replacing the immune cells destroyed by the treatment.
Previous studies have found that patients who undergo stem cell transplants have a slightly higher risk of developing secondary cancers caused by the chemotherapy and/or radiation. However, the new study did not find a statistically significant difference – 11 patients in the control group developed secondary cancer, compared with 12 patients in the transplantation group.
Researchers are continuing to analyze the data. “As years go by, there may be additional analysis that may help fine-tune the results so that we will be able to more carefully and concisely define any potential benefit of transplant,” Stiff said.
In addition to the National Cancer Institute, the study was funded by the Canadian Cancer Society Research Institute and in part by Bristol-Myers Squibb. Stiff is first author and corresponding author. Co-authors are Joseph M. Unger, M.S.; James R. Cook, M.D., Ph.D.; Louis S. Constine, M.D.; Stephen Couban, M.D.; Douglas A. Stewart, M.D.; Thomas C. Shea, M.D.; Pierluigi Porcu, M.D.; Jane N. Winter, M.D.; Brad S. Kahl, M.D.; Thomas P. Miller, M.D.; Raymond R. Tubbs, D.O.; Deborah Marcellus, M.D.; Jonathan W. Friedberg, M.D.; Kevin P. Barton, M.D.; Glenn M. Mills, M.D.; Michael LeBlanc, Ph.D.; Lisa M. Rimsza, M.D.; Stephen J. Forman, M.D.; and Richard I. Fisher, M.D.
Loyola has treated more blood cancer patients with stem cell transplants than any other center in Illinois and has one of the largest unrelated donor transplant programs in the world. Loyola physicians have performed more than 2,700 stem cell transplants, including about 150 cord blood transplants. Loyola has particular expertise in treating patients who cannot find matching donors from either their families or from the National Marrow Donor Program. Loyola receives referrals from throughout the Midwest, including other academic medical centers in Chicago. Loyola is among the first centers to use umbilical cord stem cells expanded in the laboratory before transplantation for the treatment of certain adult cancers.
The Loyola University Chicago Health Sciences Division (HSD) advances interprofessional, multidisciplinary, and transformative education and research while promoting service to others through stewardship of scientific knowledge and preparation of tomorrow's leaders. The HSD is located on the Health Sciences Campus in Maywood, Illinois. It includes the Marcella Niehoff School of Nursing, the Stritch School of Medicine, the biomedical research programs of the Graduate School, and several other institutes and centers encouraging new research and interprofessional education opportunities across all of Loyola University Chicago. The faculty and staff of the HSD bring a wealth of knowledge, experience, and a strong commitment to seeing that Loyola's health sciences continue to excel and exceed the standard for academic and research excellence. For more on the HSD, visit LUC.edu/hsd.